ストックスクリーナーアプリを入手
409.24
0.71%
2.2199
前日終値:
$407.02
開ける：
$409.39
24時間の取引高:
1.73M
Relative Volume:
0.79
時価総額：
$161.39B
収益：
$42.90B
当期純損益:
$6.52B
株価収益率:
24.00
EPS:
17.05
ネットキャッシュフロー:
$6.72B
1週間 パフォーマンス:
-4.45%
1か月 パフォーマンス:
-6.39%
6か月 パフォーマンス:
-26.26%
1年 パフォーマンス:
-28.45%
1日の値動き範囲:
$404.57
$413.35
1週間の範囲:
$404.57
$431.44
52週間の値動き範囲:
$404.57
$627.88
Thermo Fisher Scientific Inc Stock (TMO) Company Profile
名前
Thermo Fisher Scientific Inc
セクター
電話
(781) 622-1000
住所
168 THIRD AVENUE, WALTHAM, MA
TMO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TMO
Thermo Fisher Scientific Inc
|
409.76 | 161.39B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
193.79 | 142.37B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
486.43 | 35.14B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
107.11 | 30.64B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
153.44 | 27.06B | 15.41B | 1.37B | 2.11B | 7.50 |
Thermo Fisher Scientific Inc Stock (TMO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-10 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2024-12-23 | 開始されました | Scotiabank | Sector Perform |
| 2024-10-14 | 開始されました | Redburn Atlantic | Buy |
| 2024-10-01 | 開始されました | Stephens | Overweight |
| 2024-08-28 | 開始されました | Wells Fargo | Overweight |
| 2024-06-03 | 再開されました | Jefferies | Buy |
| 2024-03-18 | 再開されました | Citigroup | Neutral |
| 2024-01-24 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2024-01-08 | ダウングレード | Bernstein | Outperform → Mkt Perform |
| 2023-12-18 | 開始されました | HSBC Securities | Buy |
| 2023-12-13 | 開始されました | Wolfe Research | Outperform |
| 2023-10-26 | ダウングレード | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2023-10-25 | アップグレード | Wells Fargo | Underweight → Equal Weight |
| 2023-09-28 | 開始されました | Bernstein | Outperform |
| 2023-09-06 | 再開されました | Citigroup | Buy |
| 2023-07-19 | 開始されました | Raymond James | Outperform |
| 2023-07-19 | 繰り返されました | Robert W. Baird | Outperform |
| 2023-07-13 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2023-04-04 | 繰り返されました | Barclays | Overweight |
| 2022-12-14 | 開始されました | Deutsche Bank | Buy |
| 2022-12-07 | 開始されました | RBC Capital Mkts | Outperform |
| 2022-10-27 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2022-08-25 | 開始されました | Credit Suisse | Neutral |
| 2022-04-25 | ダウングレード | Wells Fargo | Equal Weight → Underweight |
| 2022-01-26 | 再開されました | Barclays | Overweight |
| 2021-10-20 | アップグレード | Citigroup | Neutral → Buy |
| 2021-10-15 | 再開されました | Cowen | Outperform |
| 2021-08-05 | 再開されました | Credit Suisse | Outperform |
| 2021-07-16 | 開始されました | The Benchmark Company | Buy |
| 2021-03-18 | アップグレード | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-03-03 | 開始されました | Barclays | Overweight |
| 2021-01-08 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2020-12-16 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-12-02 | 開始されました | Goldman | Buy |
| 2020-11-10 | 開始されました | KeyBanc Capital Markets | Sector Weight |
| 2020-09-30 | 開始されました | Atlantic Equities | Overweight |
| 2020-09-14 | 開始されました | Morgan Stanley | Overweight |
| 2020-08-20 | 再開されました | JP Morgan | Overweight |
| 2020-07-15 | アップグレード | Cleveland Research | Neutral → Buy |
| 2020-07-07 | 繰り返されました | Needham | Buy |
| 2020-04-23 | 繰り返されました | Needham | Buy |
| 2020-01-31 | 繰り返されました | Needham | Buy |
| 2020-01-22 | 開始されました | Credit Suisse | Neutral |
| 2020-01-08 | 開始されました | Wells Fargo | Equal Weight |
| 2020-01-07 | 開始されました | Citigroup | Buy |
| 2019-11-15 | 開始されました | Stifel | Buy |
| 2019-07-25 | 繰り返されました | Needham | Buy |
| 2019-07-16 | ダウングレード | Needham | Strong Buy → Buy |
| 2019-05-30 | 開始されました | Wolfe Research | Outperform |
| 2019-05-23 | 繰り返されました | Needham | Strong Buy |
| 2019-04-22 | 繰り返されました | Needham | Strong Buy |
| 2019-04-16 | 繰り返されました | BofA/Merrill | Buy |
すべてを表示
Thermo Fisher Scientific Inc (TMO) 最新ニュース
High Content Screening Market Global Forecasts 2025-2030 - GlobeNewswire
Smarter protection: New Class II biological safety cabinet - Labmate Online
Thermo Fisher Scientific Inc. (TMO): Among Richard Chilton’s Stock Picks with Huge Upside Potential - Yahoo Finance
Thermo Fisher Scientific to Present at BofA Securities 2025 Health Care Conference on May 13 - BioSpace
Thermo Fisher’s new biosafety cabinet offers improved lab safety and user experience - BioSpectrum Asia
Pharmaceutical CDMO Market Set to Surpass $315.08 Billion by 2034, Driven by 7.24% CAGR - GlobeNewswire Inc.
Thermo Fisher CEO Marc Casper to Share Strategic Updates at Major Healthcare Conference - Stock Titan
Benzyl Alcohol Market Scope: Growth, Share, Value, Size, - openPR.com
Global Raman Spectroscopy Market Is Booming So Rapidly - openPR.com
Immune Cell Engineering Market Generated Opportunities, - openPR.com
Laboratory Equipment Market Future Business Opportunities - openPR.com
Genome Engineering Market Generated Opportunities, Future - openPR.com
Is Thermo Fisher Scientific (TMO) One of the Best Falling Stocks to Buy According to Analysts? - Insider Monkey
Thermo Fisher Scientific to cut jobs at Orlando location - WFTV
RoosterBio Announces Collaboration with Thermo Fisher Scientific to Advance Cell & Exosome Therapy Manufacturing - PRWeb
THERMO FISHER SCIENTIFIC INC. SEC 10-Q Report - TradingView
Epigenetics Market Is Booming So Rapidly 2025-2032 -Illumina - openPR.com
Thermo Fisher Scientific Inc (TMO) Stock Analysis: A Closer Look at the 35.79% Potential Upside - DirectorsTalk Interviews
RoosterBio announces collaboration with Thermo Fisher to advance cell therapy manufacturing - BioSpectrum Asia
Thermo Fisher Scientific Leverages Integrated Solutions To Accelerate the Development of Biologic Therapeutics - Technology Networks
RoosterBio and Thermo Fisher Scientific Agree to Collaborate to Advance Cell and Exosome Therapy Manufacturing - Genetic Engineering and Biotechnology News
Lab Automation Market Set to Witness Significant Growth - openPR.com
Thermo Fisher commits $2bn to boost US operations - The Manufacturer
Thermo Fisher Scientific (NYSE:TMO) Collaborates With RoosterBio To Advance Cell Therapy Solutions - simplywall.st
Thermo Fisher reports Q1 growth, charts a steady course for 2025 - BioProcess International
Thermo Fisher Launches Improved Biological Safety Cabinet - Contract Pharma
RoosterBio Announces Collaboration with Thermo Fisher Scientific to Advance Cell and Exosome Therapy Manufacturing - PR Newswire
Research Grade Proteins Market to Witness Massive Growth by 2032 - openPR.com
Thermo Fisher Scientific employs an enhanced platform technology - European Pharmaceutical Manufacturer
Cell Lysis Market Growth in Future Scope 2025-2032 | Thermo - openPR.com
Thermo Fisher Scientific Inc. (NYSE:TMO) Q1 2025 Earnings Call Transcript - MSN
RoosterBio, Thermo Fisher Partner to Advance Cell & Exosome Therapy Manufacturing - Contract Pharma
Thermo Fisher (TMO) Target Price Reduced by Argus | TMO Stock Ne - GuruFocus
Thermo Fisher To Buy Phadia For $3.5 Billion - CHEManager Online
Argus Adjusts Price Target on Thermo Fisher Scientific to $470 From $620 - marketscreener.com
Thermo Fisher accelerates development of biologic therapeutics - BioSpectrum Asia
Thermo Fisher Scientific Leverages Integrated Solutions to Accelerate the Development of Biologic Therapeutics - BioSpace
Pharmacogenomics Market Detailed In New Research Report 2025 | - openPR.com
Thermo Fisher Scientific to invest $2 billion to expand US operation - Indian Pharma Post
ENCell and Thermo Fisher Scientific discuss expanded collaboration in cell and gene therapy field - koreabiomed.com
Competent Cells Market Detailed in New Research Report By 2032 | - openPR.com
Thermo Fisher Scientific Announces $2B Investment to Expand U.S. Operations - Thomasnet
Is Thermo Fisher Scientific Gaining or Losing Market Support? - Benzinga
Thermo Fisher commits $2B to US manufacturing - MedTech Dive
Revvity joins peers Thermo Fisher, Danaher in tariff warning, maintains profit outlook - MSN
Thermo Fisher Streamlines Pre-Clinical Biologic Drug Development - Contract Pharma
Thermo Fisher opens Advanced Therapies Collaboration Center in San Diego to accelerate cell therapy development - Select Science
Escherichia Coli Strain Market to Witness Massive Growth by 2032 - openPR.com
Thermo Fisher Scientific Inc (TMO) Stock Analysis: Exploring a 35.63% Potential Upside for Investors - DirectorsTalk Interviews
StockWatch: Tools Giants Foresee Revenue Impacts from Tariffs, Job Cuts - Genetic Engineering and Biotechnology News
Thermo Fisher Scientific Inc. (TMO): Among Billionaire Ken Fisher’s Healthcare Stock Picks with Massive Upside Potential - Insider Monkey
Thermo Fisher Scientific Inc (TMO) 財務データ
収益
当期純利益
現金流量
EPS
1.51%
大文字化:
|
ボリューム (24 時間):